Application no. and date | 18155724.0 (espacenet) (Federated) (European Patent Register), 20020218 | Patent/reg. no. and date | DK/EP 3342411, 20190821 | Publication date | 20180704 | Priority no. and date | GB 0104072, 20010219, GB 0124957, 20011017 | EP pub. no. and date |
EP 3342411 20180704 | Effective date | | Applicant/owner | Novartis Pharma AG, Lichtstrasse 35
4002 Basel, CH | Applicant ref. no. | SH/GP/159228 | Inventor | Wood, Jeanette Marjorie, In den Kleematten 18
4105 Biel-Benken, CH, Lane, Heidi, Kaltbrunnenweg 8
4106 Therwill, CH, O`Reilly, Terence, Drahtzugstrasse 51
4057 Basel, CH | Representative | Budde Schou A/S, Dronningens Tværgade 30, 1302 København K | Opponent | | IPC Class | A61K 31/436 (2006.01) , A61P 35/00 (2006.01) | Title | Rapamycinderivat til behandling af pancreascancer | Int. application no. | | Int. publication no. | | Related patent (certificate) | CA 2020 00007 | Status | Udløbet | Pædiatrisk forlængelse | - | Udløbsdato for pædiatrisk forlængelse | - |
|